ABOUT US
WHO IS GMH?
GMH is the first company to develop a treatment based on a digital biomarker of brain activity associated with mental health disorders.
The biomarker, named EEG-fMRI-Pattern, or EFP, is based on advanced statistical models that register brain area specific fMRI data to EEG. The company's FDA-cleared device, Prism for PTSD, uses the amygdala-based biomarker with an interactive computer simulation to help patients gain control, or agency, of their PTSD symptoms.
GMH is collaborating with key medical institutions to explore applying an EFP biomarker to treat mental disorders beyond PTSD. A pivotal study is underway to evaluate an EFP for Major Depressive Disorder (MDD) at McLean Hospital, Harvard University's large Psychiatric Hospital.
In addition, using deidentified data collected from treatments, our team of experts is developing therapy predictors, patient management tools and treatment personalization into the Prism platform.
OUR TEAM
Prof. Talma Hendler, MD, PhD
Inventor, SAB Chairperson,
Chief Medical Scientist
Oded Kraft
CEO, President
Co-founder
Rani Cohen
Executive Chairman BOD,
Co-founder
Shai Attia
VP R&D , Co-founder
Adar Shani
VP Clinical,
Regulatory & Quality Affairs
Dr. Aron Tendler
Chief Medical Officer
Kirk Thelander
Chief Commercial Officer
Pam Schwartz
VP Marketing
AWARDS
European Innovation Council
Nature Spinoff Prize
HITLAB Breakthrough Alliance (BTA)
SelectUSA Investor Summit Medtech track
Best Startup Award 2023
Red Herring Europe Winner 100
OUR PARTNERS
